Continual reassessment and related dose-finding designs
DOI10.1214/10-STS332zbMath1328.62594arXiv1011.6251WikidataQ30431500 ScholiaQ30431500MaRDI QIDQ903292
Publication date: 5 January 2016
Published in: Statistical Science (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/1011.6251
maximum likelihoodclinical trialBayesian methodsefficacydose-finding studiesmaximum tolerated dosecontinual reassessment methodtoxicitydose escalationmost successful dosephase 1 trialsphase 2 trials
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10) Medical applications (general) (92C50) Stochastic approximation (62L20)
Related Items (6)
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design efficiency in dose finding studies
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Using a one-parameter model to sequentially estimate the root of a regression function.
- Theoretical study of the continual reassessment method
- Dose-Finding Designs for HIV Studies
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method
- Continual Reassessment Method for Ordered Groups
- Design and Analysis of Phase I Clinical Trials
- Coherence principles in dose-finding studies
- Efficient Sequential Designs With Binary Data
- Miscellanea. A stopping rule for the continual reassessment method
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- Continual Reassessment Method: A Likelihood Approach
- Bayesian decision procedures based on logistic regression models for dose-finding studies
- A Curve‐Free Method for Phase I Clinical Trials
- Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Stochastic approximation with virtual observations for dose-finding on discrete levels
- Non-parametric optimal design in dose finding studies
- Continual reassessment designs with early termination
This page was built for publication: Continual reassessment and related dose-finding designs